20 March 2019
BB Healthcare Trust plc
Investment management team update
The Board of BB Healthcare Trust plc (the "Trust" or "BB Healthcare") today announces an update to the Trust's investment management team at Bellevue Asset Management AG ("Bellevue"). Bellevue has informed the Board that Dr Daniel Koller will step back from his role within the Trust's investment management team to focus on BB Biotech AG ("BB Biotech").
BB Healthcare will continue to be advised by its Investment Advisory Team of Paul Major and Brett Darke based in London. It was always expected that Dr Koller would step back as the Trust evolved, and Bellevue has confirmed that it will continue to provide in depth support to the Trust and fulfil its obligations under the delegated portfolio management agreement. BB Biotech and BB Healthcare Trust will continue to co-operate closely with their in-depth bottom-up stock selection and analytical processes.
Justin Stebbing, Chairman, commented: "The Board would like to thank Daniel for his support of Paul and Brett during the early years of this project, and we wish him continued success in the future. BB Healthcare's Investment Team has delivered strong results for investors in these early years and the Board has every confidence that they will continue to deliver moving forward."
This announcement contains inside information for the purposes of Article 7 of the Market Abuse Regulation (EU) 596/2014.
The Company's LEI is: 213800HQ3J3H9YF2UI82
For further information please contact:
Bellevue Advisors Limited |
|
Paul Major |
+44 (0)20 3326 2982 |
Brett Darke |
+44 (0)20 3871 2862 |
Claude Mikkelsen |
+44 (0)755 704 8577 |
|
|
Peel Hunt LLP |
+44 (0)20 7418 8900 |
Liz Yong, Helen Rennardson (Corporate Broking) |
|
Mark Thompson, Chris Bunstead (Sales) |
|
|
|
J.P. Morgan Cazenove |
+44 (0)20 7742 4000 |
William Simmonds |
|
Ed Murray |
|
Eddie Nissen (Sales) |
|
Oliver Kenyon |
|
|
|
Maitland/amo - Financial PR |
+44 (0)20 7379 5151 |
William Clutterbuck |
|
